TY - JOUR
T1 - Does Prostate Size Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from the REDUCE Trial
AU - Simon, Ross M.
AU - Howard, Lauren E.
AU - Moreira, Daniel M.
AU - Roehrborn, Claus
AU - Vidal, Adriana C.
AU - Castro-Santamaria, Ramiro
AU - Freedland, Stephen J.
N1 - Funding Information:
Financial disclosures: Stephen J. Freedland certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: The REDUCE study was funded by GlaxoSmithKline.
Funding Information:
Funding/Support and role of the sponsor: This study was supported by GlaxoSmithKline. The sponsor played a role in the design and conduct of the study and in data collection, management, analysis, and interpretation.
Publisher Copyright:
© 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2016/5/1
Y1 - 2016/5/1
N2 - Background It has been shown that increased prostate size is a risk factor for lower urinary tract symptom (LUTS) progression in men who currently have LUTS presumed due to benign prostatic hyperplasia (BPH). Objective To determine if prostate size is a risk factor for incident LUTS in men with mild to no symptoms. Design, setting, and participants We conducted a post hoc analysis of the REDUCE study, which contained a substantial number of men (n = 3090) with mild to no LUTS (International Prostate Symptom Score [IPSS] <8). Outcome measurements and statistical analysis Our primary outcome was determination of the effect of prostate size on incident LUTS presumed due to BPH defined as two consecutive IPSS values >14, or receiving any medical (α-blockers) or surgical treatment for BPH throughout the study course. To determine the risk of developing incident LUTS, we used univariable and multivariable Cox models, as well as Kaplan-Meier curves and the log-rank test. Results and limitations Among men treated with placebo during the REDUCE study, those with a prostate size of 40.1-80 ml had a 67% higher risk (hazard risk 1.67, 95% confidence interval 1.23-2.26, p = 0.001) of developing incident LUTS compared to men with a prostate size 40.0 ml or smaller. There was no association between prostate size and risk of incident LUTS in men treated with 0.5 mg of dutasteride. The post hoc nature of our study design is a potential limitation. Conclusions Men with mild to no LUTS but increased prostate size are at higher risk of incident LUTS presumed due to BPH. This association was negated by dutasteride treatment. Patient summary Benign prostatic hyperplasia (BPH) is a very common problem among older men, which often manifests as lower urinary tract symptoms (LUTS), and can lead to potentially serious side effects. In our study we determined that men with mild to no current LUTS but increased prostate size are much more likely to develop LUTS presumed due to BPH in the future. This association was not seen in men treated with dutasteride, a drug approved for treatment of BPH. Our study reveals that men with a prostate size of 40.1-80 ml are potential candidates for closer follow-up.
AB - Background It has been shown that increased prostate size is a risk factor for lower urinary tract symptom (LUTS) progression in men who currently have LUTS presumed due to benign prostatic hyperplasia (BPH). Objective To determine if prostate size is a risk factor for incident LUTS in men with mild to no symptoms. Design, setting, and participants We conducted a post hoc analysis of the REDUCE study, which contained a substantial number of men (n = 3090) with mild to no LUTS (International Prostate Symptom Score [IPSS] <8). Outcome measurements and statistical analysis Our primary outcome was determination of the effect of prostate size on incident LUTS presumed due to BPH defined as two consecutive IPSS values >14, or receiving any medical (α-blockers) or surgical treatment for BPH throughout the study course. To determine the risk of developing incident LUTS, we used univariable and multivariable Cox models, as well as Kaplan-Meier curves and the log-rank test. Results and limitations Among men treated with placebo during the REDUCE study, those with a prostate size of 40.1-80 ml had a 67% higher risk (hazard risk 1.67, 95% confidence interval 1.23-2.26, p = 0.001) of developing incident LUTS compared to men with a prostate size 40.0 ml or smaller. There was no association between prostate size and risk of incident LUTS in men treated with 0.5 mg of dutasteride. The post hoc nature of our study design is a potential limitation. Conclusions Men with mild to no LUTS but increased prostate size are at higher risk of incident LUTS presumed due to BPH. This association was negated by dutasteride treatment. Patient summary Benign prostatic hyperplasia (BPH) is a very common problem among older men, which often manifests as lower urinary tract symptoms (LUTS), and can lead to potentially serious side effects. In our study we determined that men with mild to no current LUTS but increased prostate size are much more likely to develop LUTS presumed due to BPH in the future. This association was not seen in men treated with dutasteride, a drug approved for treatment of BPH. Our study reveals that men with a prostate size of 40.1-80 ml are potential candidates for closer follow-up.
KW - Lower urinary tract symptoms
KW - Prostate
KW - Prostatic hyperplasia
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=84951854373&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84951854373&partnerID=8YFLogxK
U2 - 10.1016/j.eururo.2015.12.002
DO - 10.1016/j.eururo.2015.12.002
M3 - Article
C2 - 26724841
AN - SCOPUS:84951854373
SN - 0302-2838
VL - 69
SP - 885
EP - 891
JO - European Urology
JF - European Urology
IS - 5
ER -